0LW Stock Overview
A biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Neovacs S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.021 |
| 52 Week High | €1.42 |
| 52 Week Low | €0.0074 |
| Beta | -167.27 |
| 1 Month Change | 58.46% |
| 3 Month Change | -84.32% |
| 1 Year Change | n/a |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0LW | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -31.6% | 1.1% | 3.4% |
| 1Y | n/a | -14.9% | 15.0% |
Return vs Industry: Insufficient data to determine how 0LW performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 0LW performed against the German Market.
Price Volatility
| 0LW volatility | |
|---|---|
| 0LW Average Weekly Movement | 247.4% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 0LW's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 0LW's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 22 | Hugo Brugiere | www.neovacs.com |
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies.
Neovacs S.A. Fundamentals Summary
| 0LW fundamental statistics | |
|---|---|
| Market cap | €5.61k |
| Earnings (TTM) | -€32.91m |
| Revenue (TTM) | €513.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs 0LW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0LW income statement (TTM) | |
|---|---|
| Revenue | €513.00k |
| Cost of Revenue | €3.20m |
| Gross Profit | -€2.69m |
| Other Expenses | €30.22m |
| Earnings | -€32.91m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -122.09 |
| Gross Margin | -524.48% |
| Net Profit Margin | -6,416.11% |
| Debt/Equity Ratio | 1.3% |
How did 0LW perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 22:24 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neovacs S.A. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Cosmin Filker | GBC AG |
| Lionel Labourdette | Kepler Cheuvreux |